Advaxis — Investor Presentation (July 2018)
30 slides from Advaxis's investor presentation, Jul 17, 2018
Slide 1: Corporate Presentation July 2018
ADVAXKIS Corporate Presentation July 2018 Nasdaq: ADXS
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding Advaxis’ ability and strategies to develop and commercialize cancer immunotherapies, timing of planned clinical trials and regulatory milestones, potential partnershi
Slide 3: Investment Highlights
Investment Highlights ADVAXIS * Global immuno-oncology market is forecasted to exceed $100B in the next few years ¢ Current immuno-oncology market is dominated by checkpoint inhibitors (CPls) that have somewhat limited efficacy in many tumor types ¢ Our solution: A differentiated approach to fight c
Slide 4: Clinical Pipeline Overview
Clinical Pipeline Overview ADVAXIS CANCERINDICATIOI IND PHASE 1 PHASE 2 PHASE 3 AIM2CERV, High-Risk, Locally Advanced Cervical AXAL Metastatic Cervical: Combination with durvalumab AstraZeneca HPV+ Head and Neck ~70% of head-and-neck cancers are HPV+ * Metastatic Prostate ADXS-PSA Combination with K
Slide 5: The Lm Platform: Foundational Science
The Lm Platform: Foundational Science Lm vectors mimic natural infection and redirect immune response against cancer through: 1. INNATE IMMUNITY: Enhanced antigen presentation activates multiple pathways and alerts and trains the immune system ADAPTIVE IMMUNITY: Mobilizes and generates a cancer-spec
Slide 6: Lm Technology Evolution: Higher Number and Better Targets / Payload
Lm Technology Evolution: Higher Number and Better Targets / Payload ADXS-HPV (AXAL) Clinical data: Prolonged survival and complete responses in cervical and anal cancer patients (monotherapy) ADXS-PSA Clinical evidence of disease stabilization and antigen spreading in prostate cancer patients along
Slide 7: Why We Are Focused on Neoantigens
are We Focused on Neoantigens? * Mutations cause cancer and also create neoantigens * Neoantigens are only found in cancer cells which makes them good therapeutic targets * T cells that target neoantigens are the common link among successful immunotherapies developed to date; e.g. checkpoint inhibit
Slide 8: ADXS-NEO
IMMUNOTHERAPIES™ ADXS-NEO Patient-specific therapies . targeting personal neoantigens based on sequencing of each patient’s tumor < —— 4 ; “=e —s— F<
Slide 9: ADXS-NEO: Lm Platform in Personalized Medicine
ADXS-NEO: Lm Platform in Personalized Medicine ¢ ADXS-NEO is a truly personalized approach, whereby the patient's immune system is activated to create a targeted T cell response to their personal neoantigens based on their unique mutations * The Lm platform’s impact on the immune system (i.e., innat
Slide 10: The Personalized ADXS-NEO Approach
The Personalized ADXS-NEO Approach SEN US Massive Parallel Sequencing of tumor biopsies Patient-specific Patient’s Hospital or Immunotherapies Treating Institution Advaxis designs vector based Treat patient with personalized P a ¥ immunotherapy vector Identify neoepitopes on nee piopes ane programme
Slide 11: ADXS-NEO: Study Design
ADXS-NEO: Study Design AMGEN [Aaa * First patient dosed June 2018 Tumor Types: Endpoints: + Metastatic Primary microsatellite n=30 (10 per tumor type) Tolerability/Safety stable colon Up to 1 year dosing cancer + Metastatic W948 Secondary squamous 33 aceon Gnetierinih histology head- 1x10®, 2x10%, o
Slide 12: ADXS-HOT
IMMUNOTHERAPIES™ ADXS-HOT Cancer-type specific therapies targeting commonly expressed public hot-spot mutations and proprietary cancer antigens
Slide 13: ADXS-HOT: Cancer-Type Specific Approach
ADXS-HOT Cancer-Type Specific Approach = ADXS-HOT constructs target both public, or shared, hotspot neoantigens and multiple proprietary tumor associated antigen targets such as oncofetal antigens (OFAs) and cancer testis antigens (CTAs), providing broad patient coverage in most common tumor types =
Slide 14: ADXS-HOT Program Overview
ADXS-HOT Program Overview = Multiple high-value product opportunities = HOT products are cancer type specific = Lead products identified (NSCLC, prostate) = Over 10 constructs identified to-date = Exclusivity anticipated through 2037 = HOT constructs impact innate immunity, adaptive immunity and cha
Slide 15: Corporate Information
ADVAXIS IMMUNOTHERAPIES™ Corporate Information
Slide 16: Intellectual Property
Intellectual Property Own or have rights to over 400 patents and applications Filing strategy provides for broad coverage opportunities across multiple disease platforms and combination therapies Multiple provisional applications submitted ¢ Claims directed to composition of matter and methods IP po
Slide 17: Partnerships
Partnerships Presenter Oesernfon AXAL Actively seeking partner for (axalimogene filolisbac) cervical cancer program ADXS-PSA € MERCK ADXS-NEO A ; N ADXS-HOT In discussions with multiple parties ADXS-HER2 RVARATANA US and Europe development and commercial rights Clinical collaboration with Keytruda G
Slide 18: Capital Structure and Cash Position
Capital Structure and Cash Position * 52.6 million shares outstanding, 61.4 million, fully diluted = 3.1 million warrants outstanding at an exercise price of $5.00, expiring in Oct’18 * Cash on hand: $58.8 million as of April 30, 2018 (no debt) * Reduced cash burn in June 2018 to ~$50M/year
Slide 19: Management Team
KennethA. Berlin Robert Petit Dr. Andres Gutierrez Molly Henderson Chief Executive Offcer chet sconnonee Chief Medical Officer Chief Financial Officer ROSETTAGENOMICS™ ets, = Ont TOVANCE Ortho = Clinical Diagnostic MGi arscEN SELLAS Vowuis ; : Vveripex Padfegdix BIOMARIN Prceywerrous ovens Gohiona{o
Slide 20: Multiple Milestones Ahead
Multiple Milestones Ove PROGRAM MILESTONE TARGET/ STATUS ADDER TTF a + Announce planned IST in Head and Neck Cancer 2018 (axalimogene filolisbac) ADXS-PSA + Metastatic Prostate Ph1/2 Combination with pembrolizumab Q1 2019 + Part B Monotherapy Combination Therapy Data (12-mo PFS and OS) + Ph 1 clinic
Slide 21: Pathway to Creating Shareholder Value
Pathway to Creating Shareholder Value Redefined company focus on high-value assets by streamlining the HPV program = Seeking partner for AXAL in cervical cancer in the US and Europe = Discussing IST opportunity for AXAL in HPV+ head-and-neck cancer Positioning the company for success in the neoantig
Slide 22: Thank you
ADVAXKIS Thank you Nasdaq: ADXS
Slide 23: Supporting Information
ADVAXIS IMMUNOTHERAPIES™ Supporting Information
Slide 24: AXAL: GOG-0265 Efficacy Data
AXAL: GOG-0265 Efficacy Data Deus HPV-associated cancers studied: >) GOG-0265: Unprecedented improvement of survival rates in cervical cancer, anal cancer, and recurrent/metastatic cervical cancer® head and neck cancer’ 7 : 4 12-month and median overall survival Phase 2 trials!2 | omens odie mmodel-
Slide 25: Safety Profile of ADXS11-001
1n (%) Adverse Events (=192)? Safety Profileof ADXS11-001 jeemeatens anGeades Cardiac disorders Tachycardia 15 (7.8%) 0 Gastrointestinal disorders Diarrhoea 10 (5.2%) ‘Nausea 54 (28.1%) a . Vomiting 48 (25.0%) The largest clinical experience General disorders and administration site with Lm-based im
Slide 26: The Lm Technology Key Characteristics and Competitive Advantages
The Lm Technology Key Characteristics and Competitive Advantages ADVAXIS Feature Lm Attributes? Flexibility / Capacity Synergy Other Mechanisms Mechanistic Effects Applicability Characteristics Potential Competitive Advantages + Access multiple VO pathways including innate immune stimulation, ¥ Uniq
Slide 27: ADXS-NEO Preclinical AACR 2018 Poster
ADXS-NEO Preclinical AACR 2018 Poster Mh Context: « Frameshift mutations are estimated to generate up to nine times more neoantigens per mutation compared with in-frame mutations’ « Among neoantigen companies, only our Lm platform can accommodate full length frameshifts (>90 amino acids) Result: « A
Slide 28: ADXS-HOT Preclinical AACR 2018 Poster
ADXS-HOT Preclinical AACR 2018 Poster Mh Objective: * To identify and target common hotspot mutations and to determine if the ADXS-HOT platform could effectively target those hotspots and control tumor growth Results: « ADXS-HOT and « ADXS-HOT therapy and significantly ADXS-HOT will move into the cl
Slide 29: Other Data Presented at AACR
Other Data Presented at AACR 201 ADVAXIS ¢ Poster 1: Neoantigens that fail to elicit measurable T cell responses following peptide immunization can control tumor growth when delivered using a Listeria-based immunotherapy platform Conclusion: Data suggest that neoantigen expression using the Lm-based
Slide 30: Target Selection is Critical
Target Selectionis Critical ADVAXIS Al HOT targets hotspot mutations as well as proprietary oncofetal and cancer testis antigens What is a “Hotspot” mutation?! 2 What are OFA/CTAs? ° Hotspots are somatic mutations frequently observed in * OFA/CTAsare expressed in up to 100% of patients multiple pati